AstraZeneca Newswire (Page 6)

AstraZeneca Newswire (Page 6)

Comprehensive Real-Time News Feed for AstraZeneca. (Page 6)

Results 101 - 120 of 4,776 in AstraZeneca

  1. AstraZeneca (AZN) Given a GBX 6,000 Price Target at Berenberg BankRead the original story w/Photo

    Apr 26, 2018 | Daily Political

    ... other analysts have also issued reports on the stock. Barclays restated an "overweight" rating on shares of AstraZeneca in a research report on Monday, January 22nd. Citigroup reiterated a "buy" rating and set a GBX 6,000 ($83.68) target price on ...

    Comment?

  2. AstraZeneca (AZN) Receives GBX 5,150.15 Average Target Price from AnalystsRead the original story w/Photo

    Apr 25, 2018 | IntersportsWire

    Shares of AstraZeneca have earned an average recommendation of "Hold" from the twenty-four analysts that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company.

    Comment?

  3. AstraZeneca's (AZN) "Overweight" Rating Reiterated at JPMorgan ChaseRead the original story w/Photo

    Apr 25, 2018 | AmericanBankingNews.com

    ... analysts also recently issued reports about the stock. Barclays restated an "overweight" rating on shares of AstraZeneca in a report on Monday, January 22nd. Berenberg Bank boosted their target price on shares of AstraZeneca from GBX 5,800 ($80.89) ...

    Comment?

  4. AstraZeneca (AZN) Given a GBX 3,750 Price Target at Goldman SachsRead the original story w/Photo

    Apr 25, 2018 | Daily Political

    ... also recently weighed in on the stock. JPMorgan Chase set a GBX 5,500 ($76.71) price target on shares of AstraZeneca and gave the stock a buy rating in a research note on Tuesday. Berenberg Bank set a GBX 6,000 ($83.68) price target on shares of ...

    Comment?

  5. Rounds Report: Eleven Biotherapeutics Traded Further North While The...Read the original story w/Photo

    Apr 25, 2018 | Seeking Alpha

    ... 2017, Elevent commenced a trial at the US National Cancer Institute ("NCI") - to assessing Vicinium combo with AstraZeneca (NYSE: AZN )'s immune checkpoint inhibitor, Imfinzi for high-grade non-muscle invasive bladder cancer ("NMIBC"). If the data ...

    Comment?

  6. Goldman Sachs Analysts Give AstraZeneca (AZN) a GBX 3,750 Price TargetRead the original story w/Photo

    Apr 24, 2018 | IntersportsWire

    ... Credit Suisse Group reiterated an "outperform" rating and issued a GBX 5,800 ($80.89) target price on shares of AstraZeneca in a research note on Tuesday, February 20th. JPMorgan Chase set a GBX 5,500 ($76.71) target price on AstraZeneca and gave ...

    Comment?

  7. Berenberg Bank Reiterates GBX 6,000 Price Target for AstraZenecaRead the original story w/Photo

    Apr 24, 2018 | AmericanBankingNews.com

    ... the stock. Liberum Capital reiterated a "hold" rating and issued a GBX 5,000 ($69.74) target price on shares of AstraZeneca in a research note on Tuesday. Shore Capital reiterated a "hold" rating and issued a GBX 4,965 ($69.25) target price on ...

    Comment?

  8. EPS for Halyard Health, Inc. (HYH) Expected At $-0.04; Nwq Investment ...Read the original story w/Photo

    Apr 24, 2018 | Hill Country Times

    ... $68.20M in 2017Q4. It also upped Globus Med Inc (NYSE:GMED) stake by 375,234 shares and now owns 1.25M shares. Astrazeneca Plc (NYSE:AZN) was raised too. Among 7 analysts covering Halyard Health Inc ( NYSE:HYH ), 4 have Buy rating, 1 Sell and 2 ...

    Comment?

  9. AstraZeneca: Cancer-drug combo stumbles in trialRead the original story w/Photo

    Apr 24, 2018 | MarketWatch

    AstraZeneca PLC reported negative results on Tuesday from a clinical study that examined a combination of drugs for patients with lung cancer. The pharmaceutical major said that a sub-study that formed part of a phase-3 clinical trial, and which examined Imfinzi in combination with tremelimumab for patients with one variant of metastatic non-small cell lung cancer, or NSCLC, didn't show statistically significant improvements in survival metrics compared with standard chemotherapy.

    Comment?

  10. Rounds Report: Eleven Train Took Off While Improved FDA Policy Favors Infectious Disease InnovatorsRead the original story w/Photo

    Apr 24, 2018 | Seeking Alpha

    ... are most interested in the firm's long-term prospects. And, we elucidated that the combinations of Vicinium with AstraZeneca (NYSE: AZN )'s immune checkpoint inhibitor, Imfinzi is the crown jewel of the pipeline. It has a robust chance of delivering ...

    Comment?

  11. AstraZeneca and the Revolving DoorRead the original story w/Photo

    Apr 23, 2018 | GuruFocus.com

    Biotech is not especially notorious as a revolving door industry, but perhaps investors should take a closer look, specifically at AstraZeneca At the end of last week, director of the FDA's Division of Pulmonary, Allergy, and Rheumatology Products Dr. Badrul Chowdhury announced his move to British big pharma firm AstraZeneca PLC as the new vice president of research and development at its biologics unit. While there's nothing inherently wrong with this, it does raise some concerns.

    Comment?

  12. AstraZeneca (AZN) Getting Somewhat Favorable News Coverage, Study FindsRead the original story w/Photo

    Apr 22, 2018 | Daily Political

    News headlines about AstraZeneca have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time.

    Comment?

  13. Bruni J V & Company Boosted Stake in Lkq (LKQ) as Market Valuation...Read the original story w/Photo

    Apr 22, 2018 | Hill Country Times

    ... to 54,212 shares, valued at $6.79 million in 2017Q4, according to the filing. It also increased its holding in Astrazeneca Plc (NYSE:AZN) by 36,750 shares in the quarter, for a total of 79,666 shares, and has risen its stake in Ishares Tr (IBB). ...

    Comment?

  14. Shore Capital Reaffirms "Hold" Rating for AstraZenecaRead the original story w/Photo

    Apr 20, 2018 | AmericanBankingNews.com

    ... AZN has been the subject of a number of other research reports. Jefferies Group upped their target price on AstraZeneca from GBX 5,250 ($75.17) to GBX 5,350 ($76.60) and gave the stock a "buy" rating in a research report on Thursday, March 9th. ...

    Comment?

  15. AstraZeneca (AZN) - Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Apr 20, 2018 | Daily Political

    Several brokerages have updated their recommendations and price targets on shares of AstraZeneca in the last few weeks: 4/19/2018 - AstraZeneca had its "hold" rating reaffirmed by analysts at Shore Capital. They now have a GBX 4,965 price target on the stock.

    Comment?

  16. AstraZeneca (AZN) Downgraded byRead the original story w/Photo

    Apr 19, 2018 | AmericanBankingNews.com

    ... reports. Liberum Capital reaffirmed a "buy" rating and issued a GBX 5,100 ($73.02) price objective on shares of AstraZeneca in a research note on Thursday, April 27th. Barclays reaffirmed an "overweight" rating and issued a GBX 6,000 ($85.91) price ...

    Comment?

  17. AstraZeneca (AZN) Downgraded by BidaskClub to HoldRead the original story w/Photo

    Apr 19, 2018 | AmericanBankingNews.com

    A number of other analysts also recently issued reports on AZN. Leerink Swann reiterated an "outperform" rating and set a $36.00 price target on shares of AstraZeneca in a research report on Wednesday, May 17th.

    Comment?

  18. AstraZeneca's (AZN) "Hold" Rating Reaffirmed at Shore CapitalRead the original story w/Photo

    Apr 19, 2018 | AmericanBankingNews.com

    ... analysts have also issued reports about the company. JPMorgan Chase set a GBX 5,500 ($78.75) target price on AstraZeneca and gave the company a "buy" rating in a research report on Thursday, January 4th. Deutsche Bank reaffirmed a "buy" rating and ...

    Comment?

  19. Momenta Pharmaceuticals (MNTA) Shareholder Sector Gamma As Has Cut...Read the original story w/Photo

    Apr 19, 2018 | Hill Country Times

    ... August 2 with "Buy" rating. Sector Gamma As, which manages about $594.94M US Long portfolio, upped its stake in Astrazeneca Plc (NYSE:AZN) by 156,100 shares to 896,771 shares, valued at $31.12M in 2017Q4, according to the filing. It also increased ...

    Comment?

  20. AstraZeneca (AZN) Given Hold Rating at Shore CapitalRead the original story w/Photo

    Apr 19, 2018 | IntersportsWire

    ... Credit Suisse Group restated an "outperform" rating and issued a GBX 5,800 ($83.05) price objective on shares of AstraZeneca in a report on Wednesday. Goldman Sachs set a GBX 3,750 ($53.69) price objective on AstraZeneca and gave the company a ...

    Comment?